A recurrent giant cell tumor of bone treated with denosumab.
Although the giant cell tumor of bone is generally classified as a benign tumor it can rarely metastasize and has a potential risk of local recurrence. We want to report about a female patient who suffered from a recurrence of a giant cell tumor of bone after the implantation of a total endoprosthesis of the knee joint. We have treated her with denosumab, which is a receptor activator of nuclear factor kappa-B ligand inhibitor. In this case report we want to present a new option to treat this kind of neoplasm.
Department of Orthopaedics, Klinikum Wels-Grieskirchen , Wels, Austria.
Nicola
N
Stadler
Department of Orthopaedics, Klinikum Wels-Grieskirchen , Wels, Austria.
Thomas
T
Fingernagel
Department of Orthopaedics, Klinikum Wels-Grieskirchen , Wels, Austria.
Stefan G
SG
Hofstaetter
Department of Orthopaedics, Klinikum Wels-Grieskirchen , Wels, Austria.
Klemens
K
Trieb
bone; denosumab; tumor